Join
Live feed
·
PRReleasevia Quantisnow
Mineralys Therapeutics Inc. logo

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

ByQuantisnow·Wall Street's wire, on your screen.
MLYS· Mineralys Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MLYS (Mineralys Therapeutics Inc.) and more on Quantisnow.